Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
47 hedge funds and large institutions have $260M invested in Adaptimmune Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.
0% more capital invested
Capital invested by funds: $259M → $260M (+$781K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 49 → 47 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.77M |
| 2 |
O
OrbiMed
New York
|
+$2.69M |
| 3 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$2.35M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
+$1.55M |
| 5 |
NLVP
New Leaf Venture Partners
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$6.66M |
| 2 |
Millennium Management
New York
|
-$2.28M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.27M |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$636K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$595K |
ADAP Hedge Fund Activity: Q2 2016 in Review
47 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2016, worth a combined $260M — up 0.3% from $259M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ADAP and 5 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 10 added.
The largest buyer was Adage Capital Partners, adding an estimated $3.77M. The largest seller was Foresite Capital Management II, cutting an estimated $6.66M.
- 47 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2016, down from 49 in Q1 2016.
- Funds reported $260M of Adaptimmune Therapeutics stock for Q2 2016, up 0.3% quarter-over-quarter.
- 5 funds opened new Adaptimmune Therapeutics positions in Q2 2016 and 7 closed out, a net change of -2 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2016 was Adage Capital Partners, an estimated $3.77M added.
- The largest Adaptimmune Therapeutics seller in Q2 2016 was Foresite Capital Management II, an estimated $6.66M sold.
Based on aggregated 13F filings for Q2 2016.